Abstract
Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19
Highlights
Treatments for COVID-19 remain urgent and necessary despite increasing vaccine distribution
Patients were treated with bamlanivimab or a combination of casirivimab and imdevimab according to manufacturer and Food and Drug Administration (FDA) guidelines[3,4] and monitored for 30 days
The monoclonal antibody (mAb)-treated patients had a median body mass index of 35.8 (IQR, 30-40) and a mean (SD) age of 50 (19) years, and 114 (56.7%) met 2 or more high-risk criteria
Summary
Treatments for COVID-19 remain urgent and necessary despite increasing vaccine distribution. Studies suggest that monoclonal antibody (mAb) therapies prevent progression in early disease.[1,2] In late 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for 2 mAb therapies, bamlanivimab and a combination of casirivimab and imdevimab, to treat COVID-19.3,4 previous mAb studies[1,2] with a total of 852 participants (577 in one study[1] and 275 in the other2) did not report a reduction in patient mortality, and only 5 participants across both trials (0.6%) were Native American. We present a retrospective quality improvement study on an early mAb treatment program for high-risk Native American patients at the Whiteriver Service Unit (WRSU), a rural acute care facility that serves as the primary hospital and public health department on the Fort Apache Indian Reservation in eastern Arizona
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
